Caplin Point Laboratories Limited — Board Meeting, 15-05-2025: Outcome of Board Meeting

Caplin Point has announced a board meeting approving the financial results for the quarter and half-year, highlighting a strong start to FY25 with total revenue of ₹2,034 Cr (+15.5% YoY) and PAT of ₹541 Cr (+17.3%). EBITDA margin improved to 36.5%, driven by new product launches and cost-efficient, asset-light outsourcing, especially in Emerging Markets. Its US arm, Caplin Steriles, secured 8 new ANDA approvals and targets 10-12 more in FY26. An interim dividend of ₹3/share was declared. Robust cash reserves of ₹1,180 Cr underpin a ₹1,000+ Cr capex plan focused on capacity expansion and backward integration.